{"entity":{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","aka":[],"tldr":"Gynaecological oncologist and hereditary cancer expert who became President of Deutsche Krebshilfe, Germany's largest cancer charity, in 2026.","summary":"Professor Rita Schmutzler is Präsidentin of the Stiftung Deutsche Krebshilfe, the German cancer aid foundation founded in 1974 by Mildred Scheel; German Wikipedia records that she took up the presidency in February 2026, succeeding Anne-Sophie Mutter. A gynaecologist specialising in hereditary breast and ovarian cancer, she directed the Center for Familial Breast and Ovarian Cancer and the National Center for Familial Tumor Diseases at Cologne University Hospital from 2012 until her emeritus status in 2025. The foundation's executive board (Vorstand) comprises Gerd Nettekoven, Lutz M. Heitmüller and Franz Kohlhuber, with Charlotte Niemeyer chairing the Stiftungsrat.","asOf":"2026-09-10","links":[{"label":"Source: Deutsche Krebshilfe organisation page","url":"https://www.krebshilfe.de/informieren/ueber-uns/organisation/"}],"tags":["leadership","clinician-scientist","charity","hereditary-cancer"],"related":[],"cancers":["breast-hr-positive","tnbc","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["deutsche-krebshilfe"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Präsidentin of the Stiftung Deutsche Krebshilfe (2026-)","institutionId":"deutsche-krebshilfe","specialisms":["Hereditary breast and ovarian cancer","Gynaecological oncology","Cancer prevention","Cancer genetics"],"profiles":[{"label":"Institution organisation page","url":"https://www.krebshilfe.de/informieren/ueber-uns/organisation/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmutzler+RK%5BAuthor%5D"}],"papers":[{"title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer","journal":"JAMA Oncology","year":2017,"doi":"10.1001/jamaoncol.2017.1007"},{"title":"Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers","journal":"JNCI: Journal of the National Cancer Institute","year":2017,"doi":"10.1093/jnci/djw302"},{"title":"Erste zielgerichtete Therapie bei Ovarialkarzinom für BRCA1/2-Mutationsträgerinnen zugelassen","journal":"Medizinische Genetik","year":2015,"doi":"10.1007/s11825-015-0047-1"}]},"route":"/people/rita-schmutzler/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"institution":[{"id":"deutsche-krebshilfe","kind":"institution","name":"Deutsche Krebshilfe","route":"/institutions/deutsche-krebshilfe/"}],"paper":[{"id":"paper-hahnen-geparsixto-germline-brca-jama-oncol-2017","kind":"paper","name":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","route":"/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/"}]}}